Genprex, Inc. (GNPX)

NASDAQ: GNPX · IEX Real-Time Price · USD
1.57
0.01 (0.51%)
May 18, 2022 11:32 AM EDT - Market open
Market Cap75.10M
Revenue (ttm)n/a
Net Income (ttm)-18.83M
Shares Out47.90M
EPS (ttm)-0.42
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume56,473
Open1.56
Previous Close1.56
Day's Range1.53 - 1.60
52-Week Range1.17 - 4.07
Beta-1.04
AnalystsBuy
Price Target6.63 (+322.8%)
Earnings DateMay 16, 2022

About GNPX

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

IndustryBiotechnology
IPO DateMar 29, 2018
CEOJ. Rodney Varner
Employees17
Stock ExchangeNASDAQ
Ticker SymbolGNPX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for GNPX stock is "Buy." The 12-month stock price forecast is 6.63, which is an increase of 322.83% from the latest price.

Price Target
$6.63
(322.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference

Live panel discussion will explore considerations with respect to positioning of cell-based and other emerging immunotherapy platforms in solid tumors AUSTIN, Texas , May 9, 2022 /PRNewswire/ -- Genprex...

1 week ago - PRNewsWire

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

Company achieves major milestones in clinical development programs in 2022 Patient treatment in Acclaim-2 clinical trial commences AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or...

1 week ago - PRNewsWire

Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022

Presentations to highlight the Company's gene therapies for cancer and diabetes AUSTIN, Texas , April 18, 2022 /PRNewswire/ -- Genprex, Inc.  ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-sta...

1 month ago - PRNewsWire

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy...

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces it has opened its Acclaim-2 clinical trial for patient enrollment.

1 month ago - Business Wire

Genprex to Participate in Upcoming Investor Conference in March

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces participation in March conferences.

1 month ago - Business Wire

Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA™ Immunogene Therapy in Combina...

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces the dosing of its first patient in its Acclaim-1 clinical trial in non-small cell lung cancer

2 months ago - Business Wire

Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces participation in February conferences.

3 months ago - Business Wire

4 ‘Must Watch' Penny Stocks Making Big Moves After Latest News

4 names for your penny stocks list this week. The post 4 ‘Must Watch' Penny Stocks Making Big Moves After Latest News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:GATOINDOSVFD
3 months ago - PennyStocks

Preclinical Data Show Potential for Use of Genprex's ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Preclinical data finds that Genprex's ONCOPREX Nanoparticle Delivery System may be a potential platform for colon cancer

3 months ago - Business Wire

Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell ...

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announced a plan to accelerate the opening of clinical trial sites for the Acclaim-1 clinical trial.

4 months ago - Business Wire

Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company's Gene Therapies in Cancer...

AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces its conference participation for January 2022.

4 months ago - Business Wire

Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag

The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.

4 months ago - Zacks Investment Research

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex expands its clinical development pipeline to include Small Cell Lung Cancer.

4 months ago - Business Wire

Genprex up by 130% after receiving FDA fast track designation

Genprex Inc (NASDAQ: GNPX) is a clinical-stage gene therapy organization that concentrates on the development of life-changing gene therapies to treat people with diabetes and cancer. The company announ...

4 months ago - Invezz

Genprex stock more than doubles on very heavy volume after FTD granted for cancer treatment

Shares of Genprex Inc. GNPX, +121.37% skyrocketed 121% on massive volume in afternoon trading Monday, after the gene therapy company said its Reqorsa Immunogene Therapy was granted Fast Track Designatio...

4 months ago - Market Watch

GNPX Stock: 5 Things to Know as Genprex Rockets Higher

Shares of GNPX stock are soaring higher after the FDA granted fast track designation (FTD) for the company's lead drug candidate, REQORSA. The post GNPX Stock: 5 Things to Know as Genprex Rockets Higher...

4 months ago - InvestorPlace

8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI, WAVE

We're diving into the top penny stocks to watch today as several names in the space see major movement on Monday alongside heavy trading. The post 8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GN...

4 months ago - InvestorPlace

Why Genprex Shares Are Soaring Today

Genprex Inc (NASDAQ: GNPX) is trading higher Monday after the company announced it received U.S. Food and Drug Administration Fast Track Designation (FTD) for REQORSA Immunogene Therapy in combination w...

4 months ago - Benzinga

Genprex's Lead Cancer Program Scores Second FDA Fast Track Tag For Lung Cancer Setting

The FDA has granted Fast Track Designation for Genprex Inc's (NASDAQ: GNPX) lead drug candidate, Reqorsa Immunogene combination therapy. The designation covers Reqorsa combined with Merck & Co Inc's (NY...

4 months ago - Benzinga

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for th...

AUSTIN, Texas--(BUSINESS WIRE)--Genprex Received FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Keytruda for Non-Small Cell Lung Cancer

4 months ago - Business Wire

Genprex to Present in November CEO Roadshow Webinar

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present on November 17 at 11 a.m. ET with CEO Roadshow.

6 months ago - Business Wire

5 Top Penny Stocks To Buy For Under $5 On Webull Today

Are these penny stocks on your Webull watch list? The post 5 Top Penny Stocks To Buy For Under $5 On Webull Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:GRNQMITQSYNUAMY
6 months ago - PennyStocks

Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D.

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer an...

7 months ago - Business Wire

Genprex to Participate in September Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer an...

7 months ago - Business Wire

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination...

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer an...

10 months ago - Business Wire